Quantcast

Latest Alkylating antineoplastic agents Stories

2015-04-19 12:22:32

- Data support VAL-083's importance as a potential therapy for non-small cell lung cancer (NSCLC), including drug-resistant NSCLC - VANCOUVER, British Columbia and MENLO PARK, Calif.,

2014-10-31 08:26:03

- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.

2014-10-09 08:27:59

DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct.

2014-08-05 23:00:31

LifeScienceIndustryResearch.com adds latest Report on “Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report” to its store.

2014-06-30 13:06:13

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc.

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with

2014-04-22 08:32:53

FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for